Irish pharma major Shire (LSE: SHP) announced on Friday that the US Food and Drug Administration (FDA) had granted approval for Takhzyro (lanadelumab), its novel preventative therapy for hereditary angioedema (HAE).
Takhzyro is the only monoclonal antibody that provides targeted inhibition of plasma kallikrein, an enzyme that is poorly regulated in patients suffering from HAE. Shire recommends a dosage of 300mg once every two weeks, via subcutaneous injection that the company reports most patients were able to self-administer in under a minute.
HAE affects one in every 50,000 people, and can result in unpredictable, difficult-to-manage episodes of swelling throughout the body. Of that group, around 50% will experience laryngeal swelling in their lifetime, 30% of whom will die as a result.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze